Blink® Tears eye drops + Investigational lipid eye drops
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Acuity
Conditions
Visual Acuity
Trial Timeline
Sep 16, 2020 → Oct 10, 2020
NCT ID
NCT06131476About Blink® Tears eye drops + Investigational lipid eye drops
Blink® Tears eye drops + Investigational lipid eye drops is a phase 1 stage product being developed by Johnson & Johnson for Visual Acuity. The current trial status is completed. This product is registered under clinical trial identifier NCT06131476. Target conditions include Visual Acuity.
What happened to similar drugs?
3 of 9 similar drugs in Visual Acuity were approved
Approved (3) Terminated (3) Active (5)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06131476 | Phase 1 | Completed |
Competing Products
13 competing products in Visual Acuity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 35 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| Ranibizumab | Novartis | Approved | 43 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 32 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 22 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 26 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 27 |